Natalie Kirchhofer 博士

专利律师

2018 年成为合伙人

Bleichstrasse 14
D-40211 Duesseldorf
Germany

Phone +49 211 90490-0
Fax +49 211 90490-49

mail@cohausz-florack.de

vCard

Vita (PDF)

个人详细资料

Natalie Kirchhofer 博士是化学、制药和生命科学领域的专家。作为 COHAUSZ & FLORACK 的专利律师和合伙人，她为德国和海外的化学和制药公司以及生物技术初创企业提供所有有关知识产权问题的咨询。客户尤其受益于她的战略建议，以及她在口头谈判中出色的专长、分析技巧和口才。 Natalie Kirchhofer 已经为制药行业的一些知名公司成功地进行了许多诉讼程序（特别是有效性、反对和无效诉讼），并实施了有价值的知识产权保护。她同时也是化学和药物专利法领域的撰稿人和讲师。

此外，她还担任国家和国际仲裁或其他 ADR 诉讼的联合律师、仲裁员或专家证人，特别是涉及复杂的知识产权（如专利）和科学或技术相关事项的主题，包括研发或许可活动引起的争议。在所有这些领域，她都可以充分利用她在担任知识产权战略顾问、知识产权诉讼律师和交易中知识产权尽职调查顾问期间积累的丰富经验。

她在蒂宾根大学的生物化学研究得到了德国国家学术基金会提供的奖学金资助。凭借 Fulbright 奖学金，她与纽约洛克菲勒大学的诺贝尔奖获得者 Günter Blobel 教授一起完成了一年的学术研究。随后她拿到了博士学位，期间获得了慕尼黑马克斯普朗克生物化学研究所勃林格殷格翰基金的奖学金。

在 COHAUSZ & FLORACK 接受知识产权法职业培训后，她在 2014 年获得德国专利律师资质并成为欧洲专利局代表。然后，她在纽约 Ropes & Gray LLP 的知识产权诉讼实践小组工作了六个月，在那里积累了美国专利法方面的实践经验。她还被借调到一家大型德国制药公司工作过。

Natalie Kirchhofer 于 2014 年成为 COHAUSZ & FLORACK 的专利律师，充实本公司的化学、制药和生命科学团队。 2018 年，她被任命为合伙人。她用德语、英语和法语为客户提供咨询服务。

出版物

Dr. Arwed Burrichter, Dr. Natalie Kirchhofer & Dr. Romina Kühnle

Obtaining patent term extensions in Europe

in: IAM The Guide to Life Sciences: Key issues for senior life sciences executives 2023

Download

Dr. Natalie Kirchhofer & Dr. Hannah Jenke

Germany: UPC Impact and Legislative Shifts Make Germany a Venue of Choice

Patent prosecution in Germany
in: IAM Patent Prosecution Review 2024, published by Law Business Research - IP Devision

Natalie Kirchhofer 博士

专利律师

个人详细资料

最新推荐

学习与工作经历

会员资格

专业特长

专长

出版物

Obtaining patent term extensions in Europe

Germany: UPC Impact and Legislative Shifts Make Germany a Venue of Choice

G 1/22 and G 2/22: EPO Enlarged Board of Appeal issues decision on formal entitlement to priority and the "Joint Applicants Approach" for PCT applications

Germany becomes ready for the UPC and revises Patent Act

Das neue Patentrecht - Praxishandbuch zur Reform des PatG

Mehr Weitsicht bitte!

Double trouble

Germany revises Patent Act and clears way for UPC

COHAUSZ & FLORACK successful in defending Bayer’s patent on the once-daily administration of rivaroxaban (Xarelto®)

Patenting plant inventions via the EPO after G 3/19

EUIPO sees significant rise in EU trademark applications in 2021

Double patenting – Art. 125 EPC provides legal basis for refusing a European patent application

Second medical use patents and their potential for society and research

EPO Enlarged Board of Appeal postpones decision on video-hearings

EPO video-hearings: Enlarged Board of Appeal reviews challenges on grounds of suspected partiality and exchanges board members

Dr. Regina Hock is the new President of the Federal Patent Court

Comment on oral hearings at the EPO: Leading patent attorney firms consider compulsory video conferences unlawful

EPO's Enlarged Board of Appeal to review new compulsory videoconferencing practice

EPO Boards of Appeal to apply video conferencing rule as early as January 1, 2021

Second medical use claims in pharmaceutical patents – sharp sword or toothless tiger?

Oral proceedings via video conference: The EPO Boards of Appeal propose to amend the Rules of Procedure

EPO decision on compulsory oral proceedings by videoconference

Jennifer Doudna and Emmanuelle Charpentier win the 2020 Nobel Prize in Chemistry for CRISPR/Cas

Specialisation in life sciences, pharma and chemical disputes

New draft legislation in Germany to ratify the Unified Patent Court

Deadly pitfalls and lessons learned – claiming priority at the EPO

European Patent Office denies patentability of plants and animals obtained by essentially biological processes (G 3/19 "Pepper")

Patent battle over CRISPR – EPO revokes foundational patent of the Broad Institute in last instance for formal priority defects

Handbuch Europäischer Patentprozess

New Rules of Procedure of EPO Boards of Appeal Entering into Force on January 1, 2020

EPO Administrative Council adopts new Rules of Procedure for the Boards of Appeal

Clinical trial disclosures – an obstacle to patentability in Europe

Structural reform at the EPO shows first positive results

Sprycel – new plausibility threshold for life sciences patents?

The need-to-know facts about patent term extensions in Europe

Constructive Discussion Between EPO President, Patent Attorneys, and Attorneys at Law

Patent pools in the life sciences: a potential facilitator of CRISPR commercialisation

UPC could open as early as December 2017, if not blocked by a “hard” Brexit

Using the UPC to your benefit in pharmaceuticals and life sciences

Proposed structure of the Unified Patent Court

Cross-border patent litigation in Europe: change is coming

Das Patentassessorexamen, Skript zur Prüfungsvorbereitung

A Practioner’s Guide to Obtaining U.S. Discovery in Aid of German Patent Litigation

Prodrugs and metabolites - in the twilight zone of patentability?

The must-know facts about patent term extensions in Europe

EPO Enlarged Board of Appeal rules on disclaiming positive embodiments of an invention

Key issues in building a strong life sciences patent portfolio

Patenting biotechnology inventions via the EPO

Patent-Life Cycle-Management im Pharmabereich

您

关于我们

UPC

知识产权权利

博客

了解更多

联系方式